LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

NCT04216121 · clinicaltrials.gov ↗

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Interventions

RADIATION: Local ablative therapy
PROCEDURE: Local ablative therapy

Sponsor

Universitaire Ziekenhuizen KU Leuven